

**REMARKS**


Claims 16-22 are pending in the present application. Claims 1-15 are canceled, being directed to subject matter not elected following restriction of the claims. Claim 22, directed to a method of treatment using the elected compound, is added for examination. The claims are amended to correct minor errors of grammar or to eliminate punctuation (parentheses) that might be considered improper.

The Examiner has required election in the present application among:

Group I, claims 1-5, drawn to a method for screening a compound for ability to improve memory and/or learning dysfunctions associated with schizophrenia;


Group II, claims 6-15, drawn to a therapeutic agent selected by the screening assay of Group I;



Groups III, claims 16-20, drawn to a compound of the formula I wherein Z is




;

Groups IV, V, VI, and VII, claims 16-19 each in part, drawn to a compound of formula 1 wherein Z is a moiety





or



, respectively;

And Group VIII, claim 21, drawn to a compound of the formula 2.

**For the purpose of examination of the present application, Applicants elect Group III, Claims 16-20 (and 22).**

The election is made with traverse. Specifically, Applicants submit that the Examiner should undertake examination by election of species practice whereby, if an initially elected species of Z is found patentable, then the others would be examined with an eye toward determination if a generic claim could be allowable.

**For purpose of initial search, Applicants hereby elect the species presented in claim 20, lurasidone. Claims 16-20 (and 22) encompass the elected species.**

Should there be any outstanding matters that need to be resolved in the present application, the Examiner is respectfully requested to contact Mark J. Nuell, Ph.D., Registration No 36,623 at the telephone number of the undersigned below, to conduct an interview in an effort to expedite prosecution in connection with the present application.

If necessary, the Commissioner is hereby authorized in this, concurrent, and future replies, to charge payment or credit any overpayment to our Deposit Account No. 02-2448 for any additional fees required under 37 C.F.R. § 1.16 or under § 1.17; particularly, extension of time fees.

Dated: October 23, 2008

Respectfully submitted,

By   
Mark J. Nuell

Registration No.: 36,623  
BIRCH, STEWART, KOLASCH & BIRCH, LLP  
12770 High Bluff Drive, Suite 260  
San Diego, CA 92130  
(858) 792-8855  
Attorney for Applicant